Immunocore Holdings IMCR
NASDAQ IMCR
$36.13 -1.44 (-3.85%)
As of: Sep 4, 2026 · 3:59 PM EDT

Immunocore Holdings (IMCR) Notes Payables (2019 - 2023)

Immunocore Holdings (IMCR) posted Notes Payables of $1.2 million for Q2 2023, down 94.97% sequentially from $24.6 million in Q4 2019.

Analysis

Immunocore Holdings (IMCR) Notes Payables (2019 - 2023) Analysis & Trends

Immunocore Holdings has reported Notes Payables for 2 years, with the latest figure at $1.2 million in Q2 2023.

  • Quarterly Notes Payables changed N/A year-over-year to $1.2 million in Q2 2023, while the trailing twelve-month figure through Jun 2023 was $1.2 million (changed N/A YoY) and the FY2019 annual result came in at $24.6 million, changed N/A from the prior year.
  • Notes Payables fell to $1.2 million in Q2 2023 per IMCR's latest filing, from $24.6 million in the prior quarter.
  • Over five years, Notes Payables peaked at $24.6 million in Q4 2019 and troughed at $1.2 million in Q2 2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Immunocore Holdings 1.85 Bn 965.54 Mn 114.84 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2023 1.24 Mn
Dec 31, 2019 24.63 Mn